Alzumab's (re)mission statement
How Biocon aims to take on anti-TNF-alpha mAbs by targeting CD6
The company has long maintained that the first-in-class biologic has a safety advantage over competing psoriasis biologics. Now the long-term data it is collecting from its psoriasis trials are providing a new selling point for the drug - duration of remission.
It's still unclear whether those benefits will be enough to pull